[
  {
    "question": "55 years old came with LL paresthesia and heaviness and getting worse, reaching to the UL, and intermittent abdominal pain, hyperhydrosis; recieved vaccine 2 weeks ago. What is the Dx?",
    "option_a": "AIDP",
    "option_b": "AIP",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) is the most common variant of Guillain\u2013Barr\u00e9 syndrome (GBS), an immune-mediated polyneuropathy usually triggered by preceding infections or immunizations. It is characterized by an acute, ascending, symmetric weakness with paresthesias and variable autonomic dysfunction. The underlying mechanism involves molecular mimicry where an immune response triggered by an antecedent event (such as a vaccine) cross-reacts with peripheral nerve myelin. This results in segmental demyelination of peripheral nerves and nerve roots, leading to slowed nerve conduction. Autonomic fiber involvement may cause symptoms such as hyperhidrosis and even gastrointestinal dysmotility, which could explain the intermittent abdominal pain seen in this patient. Patients typically present with lower limb paresthesia and weakness that ascends to involve the upper limbs. Autonomic dysfunction is common and may present as variations in blood pressure, arrhythmias, abnormal sweating, or even unexplained abdominal discomfort due to dysautonomia. The temporal association with vaccination (commonly 1\u20133 weeks afterward) supports the diagnosis. Evaluation includes nerve conduction studies (which demonstrate slowed conduction velocities and conduction blocks) and cerebrospinal fluid (CSF) analysis showing albuminocytologic dissociation. Differential diagnoses include acute intermittent porphyria (AIP), which also presents with abdominal pain and neurological symptoms, but typically has severe abdominal pain and a different trigger profile, and other neuropathies such as diabetic or toxic neuropathies. First-line treatments for AIDP include intravenous immunoglobulin (IVIG) and plasma exchange. Early initiation is important to prevent respiratory failure. Supportive care with monitoring of autonomic dysfunction and respiratory status is essential. In pregnancy and lactation, IVIG is the preferred treatment due to its safety profile, while plasma exchange can be used cautiously when indicated. Option A (AIDP) is correct because the patient\u2019s ascending weakness, recent vaccine history, and autonomic symptoms (hyperhidrosis and intermittent abdominal pain) are consistent with GBS. Option B (AIP) might be considered because of the abdominal pain, but AIP typically presents with severe, unremitting abdominal pain along with neuropsychiatric symptoms and is less directly associated with a recent vaccine trigger. 1. Ascending weakness with minimal sensory loss is typical of GBS. 2. Autonomic instability, including abnormal sweating and gastrointestinal symptoms, may occur in AIDP. 3. A recent immunization or infection is a common trigger for GBS. Recent guidelines from the American Academy of Neurology affirm early treatment with IVIG or plasma exchange in GBS. Research continues into optimizing immunomodulatory strategies and identifying markers for early respiratory compromise.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "35 years old presented with posterior thigh weakness and calf weakness and he can not do plantar weakness CK level X35 double normal, Dx?",
    "option_a": "Dysferlinopathy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Dysferlinopathy refers to a group of autosomal recessive muscular dystrophies due to mutations in the dysferlin gene. It encompasses both Miyoshi myopathy, which primarily affects the distal muscles (especially the calves), and Limb-Girdle Muscular Dystrophy type 2B (LGMD2B), which typically affects proximal muscles. A mutation in the dysferlin gene impairs the protein responsible for skeletal muscle membrane repair. The defective repair mechanism leads to progressive muscle fiber degeneration and necrosis, causing an elevation in creatine kinase (CK) levels often many times above normal values. Patients with dysferlinopathy may first present with weakness in the posterior thigh and calf muscles. Difficulty with functions such as plantar flexion (standing on tiptoes) is common. The patient\u2019s markedly elevated CK level (often 10- to 100-fold above normal; in this case, approximately 35 times the normal value) supports a muscle breakdown process, typical for this myopathy. Diagnosis is based on clinical assessment, markedly elevated serum CK, and further evaluation by electromyography (EMG). Muscle biopsy with immunostaining for dysferlin is definitive. Differential diagnoses include inflammatory myopathies and other forms of limb-girdle muscular dystrophy, but the pattern of muscle involvement and genetic testing help differentiate these conditions. There is currently no cure; management is supportive and focuses on physiotherapy, occupational therapy, and maintaining mobility. Avoidance of unnecessary strenuous exercise can be beneficial. Genetic counseling is recommended. During pregnancy and lactation, supportive management, physical therapy, and multidisciplinary care are essential with a focus on preserving maternal function. Option A (Dysferlinopathy) is correct as it correlates with the patient\u2019s age, pattern of posterior thigh and calf weakness, difficulty with plantar flexion, and highly elevated CK levels. Other options were not provided, but none would fit this distinct clinical picture as well. 1. Dysferlinopathy can present as either a distal (Miyoshi myopathy) or proximal (LGMD2B) myopathy. 2. Markedly elevated CK levels are a hallmark of the disease. 3. Genetic testing is critical for confirming the diagnosis. Recent research has focused on elucidating the molecular pathways of dysferlin function and exploring potential gene therapies. Current guidelines emphasize a supportive and multidisciplinary approach to management.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with proximal UL & LL weakness with dysmorphic feature, Muscle Bx: central core, Dx:",
    "option_a": "RYR1",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Central core disease is a congenital myopathy characterized by muscle weakness and structural abnormalities in muscle fibers observed on biopsy. It is closely associated with mutations in the RYR1 gene, which encodes for the ryanodine receptor involved in calcium release in muscle cells. Mutations in the RYR1 gene lead to abnormal calcium homeostasis in skeletal muscle cells, resulting in impaired muscle contraction and the formation of cores \u2013 central areas of muscle fibers that lack oxidative enzyme activity. This defect is responsible for the weakness and structural alterations seen in the disease. Patients typically present with proximal muscle weakness affecting both upper and lower limbs. Facial dysmorphism or dysmorphic features may also be seen. A key clinical correlation is the risk of malignant hyperthermia during anesthesia, which is associated with RYR1 mutations. The diagnosis is strongly supported by muscle biopsy findings that demonstrate the presence of central cores. Genetic testing further confirms a mutation in the RYR1 gene. Differential diagnoses include other congenital myopathies such as nemaline myopathy and myotubular myopathy, but these have distinct histopathologic features. Management is primarily supportive with a focus on physical and occupational therapy. It is crucial to counsel patients about the risk of malignant hyperthermia during anesthesia and ensure that anesthetic plans reflect this risk. In pregnancy and lactation, careful anesthetic planning is paramount, and multidisciplinary management is advised to monitor both maternal and fetal well-being. Option A (RYR1) is correct because the presence of central cores on muscle biopsy in a patient with proximal weakness and dysmorphic features is pathognomonic for central core disease, which is most commonly caused by mutations in the RYR1 gene. 1. Central core disease is associated with an increased risk for malignant hyperthermia. 2. Muscle biopsy showing central cores is critical for diagnosis. 3. The condition is usually inherited in an autosomal dominant pattern. Advances in genetic testing have solidified the link between RYR1 mutations and central core disease. Current research is focusing on targeted therapies and improved anesthetic protocols to reduce risks during surgery.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "55 years old pt presented with ptosis and EOM weakness, dysphagia and proximal weakness:",
    "option_a": "GCG Repeat",
    "option_b": "D4Z4",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The patient\u2019s presentation of ptosis, extraocular muscle (EOM) weakness, dysphagia, and proximal limb weakness are highly suggestive of oculopharyngeal muscular dystrophy (OPMD). This condition is associated with a trinucleotide (GCG) repeat expansion in the PABPN1 gene, leading to a polyalanine expansion. In OPMD, the abnormal expansion of the GCG repeat within the PABPN1 gene causes an expanded polyalanine tract in its protein product, which interferes with normal protein function. This leads to progressive degeneration and atrophy of muscle fibers, particularly affecting the muscles controlling the eyelids, pharynx, and proximal limbs. Clinically, OPMD typically presents in middle-aged adults with gradual onset of ptosis and dysphagia. Proximal muscle weakness may develop later in the disease course. These findings, along with the genetic abnormality, help distinguish OPMD from other neuromuscular disorders. Diagnosis is made by a combination of clinical evaluation, family history, and genetic testing to detect the GCG repeat expansion in the PABPN1 gene. Muscle biopsy can support the diagnosis but is not always necessary. Differential diagnoses include myasthenia gravis (which shows fluctuating weakness and responds to anticholinesterases) and facioscapulohumeral dystrophy (associated with D4Z4 repeat contraction and a different pattern of muscle involvement). Management of OPMD is mainly supportive. Interventions may include ptosis surgery and swallowing therapy to manage dysphagia. Regular monitoring and physiotherapy help maintain muscle strength. In the context of pregnancy and lactation, management remains supportive and largely symptomatic, ensuring that any surgical interventions are carefully timed and planned. Option A (GCG Repeat) is correct because the genetic basis of OPMD is an expansion of GCG repeats in the PABPN1 gene. Option B (D4Z4) is associated with facioscapulohumeral muscular dystrophy, which typically presents with facial and scapular weakness rather than the ptosis and dysphagia seen in this case. 1. OPMD typically presents in adults over 40 years with ptosis and dysphagia. 2. The diagnosis is confirmed by demonstrating a GCG repeat expansion in the PABPN1 gene. 3. Differentiation from myasthenia gravis and FSHD is critical due to differences in treatment and prognosis. Current research in OPMD is focused on understanding the molecular mechanisms of the polyalanine expansion and exploring potential gene-targeted therapies. Updated clinical guidelines emphasize supportive management and multidisciplinary care as the mainstay of treatment.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with scapular winging and weakness, he has very high CK:",
    "option_a": "Calpinopathy",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case involves a patient with scapular winging and muscle weakness accompanied by a very high creatine kinase (CK) level. Such a presentation is characteristic of a muscular dystrophy. Calpainopathy, also known as Limb-Girdle Muscular Dystrophy type 2A (LGMD2A), is a genetic disorder that commonly presents with proximal muscle weakness and scapular winging. Calpainopathy is caused by mutations in the CAPN3 gene that encodes the muscle-specific protease calpain-3. This enzyme is crucial for normal muscle regeneration and structural maintenance. Its deficiency leads to progressive muscle fiber degeneration and replacement by fat and fibrous tissue, resulting in markedly elevated CK levels due to muscle breakdown. The clinical findings of scapular winging and proximal weakness are common in LGMD2A. Elevated CK is seen in many muscular dystrophies due to ongoing muscle damage. The pattern of weakness \u2013 particularly of the shoulder girdle and pelvic muscles \u2013 helps differentiate it from other neuromuscular conditions. Initial evaluation includes serum CK measurement, electromyography (EMG) to look for myopathic versus neuropathic patterns, and muscle imaging. A muscle biopsy with immunohistochemistry and genetic testing (targeting the CAPN3 gene) are key to confirming a diagnosis of calpainopathy. Differential diagnoses include Facioscapulohumeral Muscular Dystrophy (FSHD), which typically involves facial muscles, and dystrophinopathies, which have a different age and gender distribution. There is no curative treatment currently. Management is supportive and includes a multidisciplinary approach with physical therapy, orthotic support, and exercise to maintain muscle strength. Regular cardiac and respiratory evaluations are recommended. In pregnancy and lactation, careful monitoring and adjustment of physical therapy may be necessary, with attention to potential musculoskeletal strain. Emerging gene therapies and clinical trials are ongoing. Option A (Calpainopathy) is correct because the clinical presentation of scapular winging, proximal muscle weakness, and markedly elevated CK levels is consistent with LGMD2A. Other options are absent or not provided, so there is no conflict in the answer choice. 1. High CK levels in a muscular dystrophy suggest active muscle fiber damage. 2. Scapular winging is a key sign in several myopathies but when combined with limb-girdle weakness and a genetic background, LGMD2A should be considered. 3. Genetic testing is essential for a definitive diagnosis. Recent studies emphasize early genetic diagnosis, which can inform family planning and potential enrollment in novel gene-therapy trials. Consensus guidelines continue to recommend comprehensive supportive care as there is no disease\u2010modifying treatment for LGMD2A at this time.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario with congenital MG, has hand involvement and proximal UL & LL weakness, Dx:",
    "option_a": "Slow channel",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Congenital myasthenic syndromes (CMS) are a group of disorders caused by genetic defects affecting neuromuscular transmission. They are distinct from autoimmune myasthenia gravis. The scenario described \u2013 with hand involvement and proximal weakness in both upper and lower limbs \u2013 aligns with a form of CMS. In the slow channel congenital myasthenic syndrome, mutations lead to prolonged opening of the acetylcholine receptor channels at the neuromuscular junction. This abnormal ion flow causes excessive calcium entry, leading to endplate myopathy and degeneration over time. The prolonged depolarization also results in fatigable weakness. Patients with slow channel CMS typically present with early-onset, non-fluctuating weakness that may affect both proximal and distal muscles, including the hands. Unlike autoimmune myasthenia gravis, there is no antibody-mediated destruction, and symptoms are present from birth or early childhood with a consistent pattern. Diagnosis is based on clinical history, electromyography (which can reveal abnormal repetitive discharges), and specialized tests. Genetic testing is crucial to identify mutations in the acetylcholine receptor subunits. Differential diagnoses include transient neonatal myasthenia (from maternal antibodies) and other forms of CMS such as fast channel syndromes. Management of slow channel CMS can be challenging. Acetylcholinesterase inhibitors, which are effective in autoimmune myasthenia gravis, are often not beneficial and may worsen symptoms in slow channel syndrome. Instead, medications like fluoxetine or quinidine (that reduce open channel duration) may be used. In pregnancy and lactation, therapy should be individualized, balancing fetal safety with maternal function; many of these agents are used cautiously after consultation with neuromuscular and maternal\u2013fetal medicine specialists. Option A (Slow channel) is correct because the clinical picture of congenital onset weakness with hand and proximal limb involvement is characteristic of slow channel CMS. Other options are not provided, so there is no discrepancy in this case. 1. Distinguish congenital myasthenic syndromes from autoimmune myasthenia gravis based on age of onset and lack of antibody-mediated pathology. 2. In slow channel CMS, prolonged receptor opening leads to calcium overload and subsequent endplate damage. 3. Specific treatments targeting channel kinetics are essential, as typical therapies for autoimmune MG may worsen the condition. Recent guidelines emphasize the importance of molecular genetic diagnosis in CMS to guide treatment. There is ongoing research into modulators of ion channel kinetics which may offer improved therapeutic options in the future.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "50s male, hx of progressive lower limb weakness with tingling and numbness and numbness for 3 months, then become static, later he had sudden Rt foot drop. Examination weakness with areflexia",
    "option_a": "Lambert",
    "option_b": "CIDP",
    "option_c": "MMN",
    "option_d": "ALS",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "The patient is a 50\u2010year\u2010old male with a history of progressive lower limb weakness, sensory disturbances (tingling and numbness), and areflexia. This mixed motor and sensory neuropathy presentation brings to mind an inflammatory demyelinating process. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is an immune-mediated disorder in which the peripheral nerves and nerve roots undergo demyelination. This results in slowed nerve conduction velocity, conduction block, and eventual axonal damage if untreated. The occasional acute deterioration, such as a sudden foot drop, can occur superimposed on a chronic process. CIDP typically presents with slowly progressive or relapsing motor and sensory deficits over a period of at least 8 weeks. The presence of areflexia is a classic sign. In this scenario, the gradual onset over 3 months followed by an acute event is consistent with a CIDP diagnosis rather than a purely motor neuropathy or a neurodegenerative condition. Diagnosis relies on clinical evaluation, nerve conduction studies (which demonstrate demyelinating features like prolonged distal latencies and conduction blocks), and cerebrospinal fluid analysis (often showing elevated protein with normal cell counts). Differential diagnoses include Multifocal Motor Neuropathy (MMN \u2014 which is typically purely motor), Amyotrophic Lateral Sclerosis (ALS \u2014 which spares sensory modalities), and peripheral neuropathies from diabetes or other metabolic causes. First-line treatments include corticosteroids, intravenous immunoglobulin (IVIg), and plasmapheresis. For patients refractory to these treatments, immunosuppressant drugs (such as azathioprine or cyclophosphamide) may be used. In pregnancy and lactation, IVIg is often preferred because of its favorable safety profile, and steroids may be used with caution after weighing risks and benefits. \u2022 Option A (Lambert) is incorrect as Lambert-Eaton Myasthenic Syndrome involves presynaptic neuromuscular junction defects and is typically associated with proximal muscle weakness and autonomic dysfunction, without sensory deficits. \u2022 Option B (CIDP) is correct given the chronic, mixed motor-sensory pattern with areflexia. \u2022 Option C (MMN) is mainly a motor neuropathy without sensory involvement. \u2022 Option D (ALS) is a motor neuron disease that typically spares sensory modalities. 1. The combination of motor and sensory deficits with areflexia strongly favors a demyelinating neuropathy like CIDP over motor-only conditions such as MMN or ALS. 2. Elevated CSF protein with a normal cell count is a supportive finding for CIDP. 3. Early diagnosis and initiation of therapy can prevent irreversible axonal loss. Recent guidelines stress the importance of early diagnosis with electrophysiological studies and recommend IVIg or corticosteroids as first-line therapies. Emerging research into biomarkers and alternative immunotherapies continues to refine management strategies for CIDP.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario suggestive of subacute combined degeneration in patient with gastric sleeve 6 months ago, B12, and MMA normal, what to do next",
    "option_a": "(Check copper level) is correct because copper deficiency myelopathy is the most likely diagnosis in a patient with a history of gastric sleeve surgery presenting with SCD",
    "option_b": "(Folate) while important in a global nutritional assessment, is less likely to explain the myelopathic picture even though folate deficiency may cause hematologic abnormalities. \u2022 The marked answer (Option C) is incorrect as it does not address the key diagnostic step (copper assessment), and neither option alone (only checking folate) is sufficient.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Subacute combined degeneration (SCD) is typically associated with vitamin B12 deficiency, which affects the dorsal columns and lateral corticospinal tracts. In a patient with neurological symptoms suggestive of SCD but with normal B12 and methylmalonic acid (MMA) levels, other nutritional deficiencies must be considered, particularly post\u2013gastric sleeve surgery. Copper deficiency myelopathy can produce a clinical picture almost identical to B12 deficiency SCD. Gastric sleeve surgery can lead to malabsorption of trace minerals like copper. Deficiency in copper impairs the function of cuproenzymes involved in neuronal maintenance, leading to demyelination of the spinal cord tracts. The clinical presentation of a myelopathy with features similar to SCD (such as sensory deficits, proprioceptive loss, and motor weakness) in a patient with a history of bariatric surgery should raise suspicion for copper deficiency, especially if B12 and MMA levels are normal. Although folate deficiency is also evaluated in nutritional assessments, it rarely causes a myelopathy similar to SCD. After excluding B12 deficiency with normal B12 and MMA levels, the next step is to assess serum copper and ceruloplasmin levels. Differential diagnoses include folate deficiency (which primarily causes hematologic, not neurological, abnormalities), vitamin E deficiency, and other nutritional deficiencies related to malabsorption following bariatric surgery. The first-line management is copper supplementation, either oral or intravenous depending on severity, along with nutritional rehabilitation. A comprehensive nutritional workup should also include folate and vitamin E evaluation; however, correction of copper deficiency is paramount given its direct impact on neurological function. In pregnancy and lactation, copper supplementation should be administered cautiously with dose adjustments and monitoring to meet both maternal and fetal needs, as copper is critical for fetal development. \u2022 Option A (Check copper level) is correct because copper deficiency myelopathy is the most likely diagnosis in a patient with a history of gastric sleeve surgery presenting with SCD-like findings and normal B12/MMA levels. \u2022 Option B (Folate) while important in a global nutritional assessment, is less likely to explain the myelopathic picture even though folate deficiency may cause hematologic abnormalities. \u2022 The marked answer (Option C) is incorrect as it does not address the key diagnostic step (copper assessment), and neither option alone (only checking folate) is sufficient. 1. Bariatric surgery increases the risk for multiple micronutrient deficiencies; copper deficiency should be strongly considered in patients with myelopathic symptoms. 2. Normal B12 and MMA levels in a clinical picture suggestive of SCD warrant evaluation of alternative causes like copper deficiency. 3. Early diagnosis and correction of copper deficiency can prevent irreversible neurological damage. Recent studies have highlighted the prevalence of copper deficiency myelopathy in post-bariatric surgery patients. Updated guidelines recommend that in patients with SCD-like findings but normal B12 profiles, serum copper and ceruloplasmin levels should be measured. There is increasing emphasis on a comprehensive nutritional evaluation in patients with a history of malabsorptive surgeries.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "What medication can cause Positive romberg & scenario suggestive of sensory neuronopathy",
    "option_a": "(pyridoxine level) is correct because it directly addresses the reversible cause of sensory neuronopathy via its association with dorsal root ganglia toxicity. Other options not related to the measurement or modulation of pyridoxine levels do not explain the positive Romberg sign and are therefore excluded.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Sensory neuronopathy represents damage primarily to the dorsal root ganglia, leading to impaired proprioception and resulting in a positive Romberg sign. Pyridoxine (vitamin B6) plays an essential role in nerve function, and both its deficiency and toxic excess have been implicated in neuropathic processes. Pyridoxine is critical for neurotransmitter synthesis and proper neuronal activity. Disruption\u2014either through severe deficiency or antagonism\u2014can lead to dorsal root ganglia toxicity. This toxicity preferentially affects large myelinated sensory fibers responsible for proprioception, hence leading to ataxia and a positive Romberg sign. Contemporary research has underscored the dose-dependent neurotoxic potential of pyridoxine and related analogs. Patients affected by pyridoxine-related sensory neuronopathy typically present with gait instability, loss of proprioceptive feedback, and a positive Romberg test. The clinical picture helps differentiate this from other neuropathies that primarily affect motor function or pain sensation. The work-up includes a detailed medication history (for potential pyridoxine antagonists or high-dose supplements) and laboratory assessment of vitamin B6 levels. Differential diagnoses include vitamin B12 deficiency (which also leads to dorsal column dysfunction), tabes dorsalis, and toxic exposures (e.g., certain chemotherapeutic agents). Electrodiagnostic studies may support the clinical findings of predominant sensory involvement. Management involves discontinuing any offending medications and correcting the pyridoxine imbalance. If deficiency is identified, careful vitamin B6 supplementation is instituted. Conversely, if toxicity is suspected from over-supplementation, dose reduction is recommended. In pregnancy and lactation, the use of pyridoxine should be carefully monitored; supplementation is generally safe at recommended doses, but excessive dosages that might lead to neurotoxicity must be avoided per current obstetrical guidelines. Option A (pyridoxine level) is correct because it directly addresses the reversible cause of sensory neuronopathy via its association with dorsal root ganglia toxicity. Other options not related to the measurement or modulation of pyridoxine levels do not explain the positive Romberg sign and are therefore excluded. 1. High doses of pyridoxine can paradoxically produce a sensory neuropathy. 2. Always consider vitamin imbalances when patients present with dorsal column signs. 3. A thorough drug history is essential in evaluating sensory neuronopathy. Recent literature emphasizes the significance of pyridoxine toxicity in neuropathy and supports early detection through laboratory evaluation. Current guidelines recommend monitoring vitamin levels in patients on high-dose supplements or medications that deplete vitamin B6.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has stiffness, neuromyotonia on EMG, recurrent LOC, but currently LOC okay, he has positive K ab what is the dx",
    "option_a": "(Isaac syndrome) is correct because it best fits the clinical picture of peripheral nerve hyperexcitability with EMG",
    "option_b": "(Morvan syndrome) is incorrect because the condition described lacks the CNS manifestations (severe insomnia, hallucinations, autonomic instability) that define Morvan syndrome.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Isaac syndrome, a form of acquired neuromyotonia, is characterized by peripheral nerve hyperexcitability. Its hallmark features include muscle stiffness, cramps, myokymia, and neuromyotonic discharges on electromyography (EMG). The presence of potassium channel (VGKC) antibodies supports an autoimmune basis. In Isaac syndrome, autoantibodies directed against voltage-gated potassium channels impair the repolarization of peripheral nerves, resulting in continuous neuronal firing. This leads to sustained muscle contractions and delayed relaxation. Although central nervous system (CNS) involvement is minimal, some cases may present with transient episodes such as loss of consciousness; however, the primary pathology remains in the peripheral nervous system. Clinically, patients present with muscle stiffness and may experience fasciculations or cramps. EMG studies reveal neuromyotonic discharges (high-frequency, spontaneous motor unit activity). While Morvan syndrome also involves VGKC antibodies, it typically presents with additional CNS signs such as severe insomnia, hallucinations, and autonomic dysfunction, which are absent in this patient. Diagnosis is based on clinical evaluation, corroborated by EMG findings of neuromyotonia and serological evidence of VGKC antibodies. The differential diagnosis includes Morvan syndrome (which would involve prominent CNS features), stiff-person syndrome (which usually involves anti-GAD antibodies and more axial rigidity), and other channelopathies. First-line management often includes symptomatic treatment with sodium channel blockers (e.g., carbamazepine or phenytoin) and anticonvulsants such as gabapentin to reduce nerve hyperexcitability. In cases with significant autoimmune activity, immunomodulatory therapy (e.g., plasmapheresis, IVIG, or corticosteroids) may be considered. For pregnant and lactating women, medication choices must be carefully balanced against potential risks; drugs with known safety profiles (such as certain anticonvulsants at adjusted doses) should be selected, and non-pharmacologic measures may be preferred when feasible. Option A (Isaac syndrome) is correct because it best fits the clinical picture of peripheral nerve hyperexcitability with EMG-confirmed neuromyotonia and VGKC antibody positivity. Option B (Morvan syndrome) is incorrect because the condition described lacks the CNS manifestations (severe insomnia, hallucinations, autonomic instability) that define Morvan syndrome. 1. Neuromyotonia on EMG is strongly indicative of Isaac syndrome. 2. VGKC antibody positivity is a pivotal diagnostic clue in differentiating between peripheral and mixed CNS involvement. 3. Always assess for central signs to rule out Morvan syndrome. Recent studies have highlighted the benefit of early immunotherapy in autoimmune channelopathies. Updated guidelines recommend a tailored approach based on the severity of symptoms and antibody titers, with ongoing research into targeted immunomodulatory treatments.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "What is the most common polio presentation",
    "option_a": "(asymptomatic) is correct as epidemiologic data indicate that around 72% of poliovirus infections occur without symptoms. Options B (meningitis), C (flu",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Poliovirus infection can have a wide spectrum of clinical presentations ranging from asymptomatic to paralytic disease. The majority of infections are subclinical, which is central to the epidemiologic understanding of poliomyelitis. After poliovirus exposure, the immune system often effectively contains the infection, resulting in an asymptomatic state in approximately 72% of cases. When the virus does invade the central nervous system, it may cause aseptic meningitis or, rarely, paralytic poliomyelitis due to anterior horn cell destruction. While the asymptomatic infection is the most common presentation, patients who develop clinical manifestations may present with flu-like symptoms or signs of aseptic meningitis. Paralytic polio, although rare (less than 1%), is the most severe form and is characterized by acute flaccid paralysis. Diagnosis of poliovirus infection is supported by clinical history, epidemiological context (such as travel or outbreaks), and laboratory tests including throat swabs and stool cultures. Differential diagnoses to consider include Guillain-Barr\u00e9 syndrome, other enteroviral infections, and acute transverse myelitis. Serological testing can help distinguish these conditions. There is no specific antiviral treatment for polio; management is mainly supportive. The cornerstone of prevention is vaccination. The use of inactivated or oral poliovirus vaccines is crucial, and vaccination guidelines must consider special populations such as pregnant and lactating women, wherein inactivated vaccines are preferred due to their safety profiles. Option A (asymptomatic) is correct as epidemiologic data indicate that around 72% of poliovirus infections occur without symptoms. Options B (meningitis), C (flu-like illness), and D (flaccid paralysis) represent less common clinical presentations, with paralytic disease being the rarest. 1. The vast majority of poliovirus infections are asymptomatic, which contributes to widespread seropositivity. 2. Paralytic poliomyelitis, although uncommon, is a public health priority due to its severity. 3. Effective vaccination programs have nearly eradicated paralytic polio in many parts of the world. Recent global health initiatives continue to emphasize poliovirus eradication via mass immunization campaigns. Current guidelines favor inactivated poliovirus vaccine (IPV) in regions where vaccine-derived poliovirus is a concern, ensuring safety in all populations including pregnant and lactating women.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Poorly controlled DM1 type 1, hg A1c 14, become controled one week started to complain of pain",
    "option_a": "(gabapentin) is correct because it is widely recognized as a first",
    "option_b": "(steroids) is contraindicated due to adverse effects on glycemic control. Options C (skin biopsy) and D (nerve biopsy) are diagnostic procedures rather than therapeutic interventions and are not routinely indicated in typical cases of diabetic neuropathy.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Painful diabetic neuropathy is a common complication of diabetes, characterized by chronic neuropathic pain due to nerve damage. It is often seen in patients with long-standing hyperglycemia and may become more apparent after rapid glycemic correction. Poor glycemic control leads to metabolic and microvascular changes that damage peripheral nerves. Paradoxically, rapid improvement of glycemic levels (a phenomenon sometimes referred to as treatment-induced neuropathy) can precipitate neuropathic pain in predisposed individuals. The abnormal neuronal excitability changes result in the persistent pain experienced by patients. Patients typically experience burning, tingling, or shooting pain in a stocking-glove distribution. The timing of pain onset following improved glycemic control is an important clinical clue. Differentiating diabetic neuropathy from other causes of pain (such as radiculopathy or other metabolic neuropathies) is essential for appropriate management. Diagnosis is primarily clinical, supported by a detailed history, physical examination, and sometimes nerve conduction studies. Differential diagnoses include vitamin B12 deficiency neuropathy, alcoholic neuropathy, and hypothyroid neuropathy. Skin biopsy may be used in select cases to assess small fiber neuropathy, but it is not a first-line diagnostic tool when the clinical picture is clear. First-line pharmacologic management of painful diabetic neuropathy includes agents like gabapentin and pregabalin, which help modulate neuronal excitability. Other first-line options include duloxetine. In cases where the patient is pregnant or lactating, the choice of neuropathic pain medication requires careful consideration; for instance, while gabapentin is commonly used, its safety in pregnancy is not as robustly established as some alternatives, so risk-benefit discussions are essential. Non-pharmacologic interventions such as physical therapy and glycemic control optimization are also critical. Option A (gabapentin) is correct because it is widely recognized as a first-line treatment for painful diabetic neuropathy. Option B (steroids) is contraindicated due to adverse effects on glycemic control. Options C (skin biopsy) and D (nerve biopsy) are diagnostic procedures rather than therapeutic interventions and are not routinely indicated in typical cases of diabetic neuropathy. 1. Rapid glycemic correction in poorly controlled diabetes can paradoxically trigger or worsen neuropathic pain. 2. Gabapentin is a mainstay of therapy for diabetic neuropathy, but individual patient factors must guide its use, especially in pregnancy. 3. A holistic approach\u2014optimizing glycemic control along with symptomatic management\u2014is key to treating painful diabetic neuropathy. Recent guidelines continue to support the use of gabapentin, pregabalin, or duloxetine as first-line treatments for painful diabetic neuropathy. Emerging research is evaluating the benefits of multimodal approaches, including lifestyle modifications and non-pharmacologic therapies, with particular attention to special populations such as pregnant or lactating patients.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Lady with history of breast cancer treated, came with one week hx of 4th and 5th digit numbness, and weakness in hand and forearm I believe, pain, chest and neck ct normal what to do next",
    "option_a": "(plexus MRI) is useful for structural evaluation but is not as sensitive for early or purely functional deficits; it is generally reserved for after electrophysiological studies. Option B (NCS/EMG) is the gold standard for delineating the nature and localization of the nerve injury. Option C (PET Scan) is intended for detecting metabolically active lesions and is not appropriate for assessing nerve function in this scenario.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "In patients with a history of breast cancer who present with unilateral upper-extremity sensory and motor deficits, it is important to distinguish between structural causes (such as tumor recurrence) and functional nerve abnormalities. Electrodiagnostic studies serve to evaluate nerve function directly, which is key in such cases. Brachial plexopathy in this setting may result from either direct neoplastic involvement or secondary effects of previous cancer treatments (e.g., radiation-induced fibrosis). Damage to myelin or axons alters nerve conduction properties, which can be detected with electrophysiological methods. Although structural imaging like CT or MRI can visualize anatomy, they may miss early or purely functional abnormalities. The patient\u2019s symptoms\u2014numbness in the 4th and 5th digits along with weakness in the hand/forearm\u2014suggest involvement of the lower components of the brachial plexus. Normal chest and neck CT scans help rule out gross mass lesions; however, the functional status of the nerves remains uncertain without further testing. The main differential diagnoses include: (1) neoplastic brachial plexopathy (e.g., recurrence of breast cancer), (2) radiation-induced plexopathy, and (3) entrapment neuropathies such as ulnar neuropathy. Nerve conduction studies (NCS) and electromyography (EMG) are the gold standards to assess nerve function and to differentiate between demyelinating versus axonal injuries. The initial step is to establish a functional diagnosis via NCS/EMG. If a neoplastic plexopathy is found, further oncological evaluation and treatment may be warranted. In cases of radiation-induced injury, management is supportive and includes physical therapy and pain management. In the context of pregnancy or lactation, electrodiagnostic studies are safe and supportive management (including physical therapy) is preferred over invasive interventions. Option A (plexus MRI) is useful for structural evaluation but is not as sensitive for early or purely functional deficits; it is generally reserved for after electrophysiological studies. Option B (NCS/EMG) is the gold standard for delineating the nature and localization of the nerve injury. Option C (PET Scan) is intended for detecting metabolically active lesions and is not appropriate for assessing nerve function in this scenario. 1. A normal CT does not rule out functional nerve deficits; NCS/EMG is the key next step. 2. Breast cancer patients are at risk for both neoplastic and treatment-related brachial plexopathies. 3. Electrophysiological studies help differentiate demyelinating from axonal injuries. Recent guidelines and studies consistently support the early use of electrodiagnostic techniques (NCS/EMG) to differentiate types of plexopathy, helping to guide subsequent management decisions in patients with a history of cancer.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Lady with hx of lung cancer, treated with radiation therapy 6 months ago came with 2 months of shoulder discomfort, weak shoulder abduction and elbow flexion, NCS/EMG showed fibs in hands and forearm muscles what to do next",
    "option_a": "(plexus MRI) is useful for structural evaluation but is not as sensitive for early or purely functional deficits; it is generally reserved for after electrophysiological studies. Option B (NCS/EMG) is the gold standard for delineating the nature and localization of the nerve injury. Option C (PET Scan) is intended for detecting metabolically active lesions and is not appropriate for assessing nerve function in this scenario.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "In patients with a history of breast cancer who present with unilateral upper-extremity sensory and motor deficits, it is important to distinguish between structural causes (such as tumor recurrence) and functional nerve abnormalities. Electrodiagnostic studies serve to evaluate nerve function directly, which is key in such cases. Brachial plexopathy in this setting may result from either direct neoplastic involvement or secondary effects of previous cancer treatments (e.g., radiation-induced fibrosis). Damage to myelin or axons alters nerve conduction properties, which can be detected with electrophysiological methods. Although structural imaging like CT or MRI can visualize anatomy, they may miss early or purely functional abnormalities. The patient\u2019s symptoms\u2014numbness in the 4th and 5th digits along with weakness in the hand/forearm\u2014suggest involvement of the lower components of the brachial plexus. Normal chest and neck CT scans help rule out gross mass lesions; however, the functional status of the nerves remains uncertain without further testing. The main differential diagnoses include: (1) neoplastic brachial plexopathy (e.g., recurrence of breast cancer), (2) radiation-induced plexopathy, and (3) entrapment neuropathies such as ulnar neuropathy. Nerve conduction studies (NCS) and electromyography (EMG) are the gold standards to assess nerve function and to differentiate between demyelinating versus axonal injuries. The initial step is to establish a functional diagnosis via NCS/EMG. If a neoplastic plexopathy is found, further oncological evaluation and treatment may be warranted. In cases of radiation-induced injury, management is supportive and includes physical therapy and pain management. In the context of pregnancy or lactation, electrodiagnostic studies are safe and supportive management (including physical therapy) is preferred over invasive interventions. Option A (plexus MRI) is useful for structural evaluation but is not as sensitive for early or purely functional deficits; it is generally reserved for after electrophysiological studies. Option B (NCS/EMG) is the gold standard for delineating the nature and localization of the nerve injury. Option C (PET Scan) is intended for detecting metabolically active lesions and is not appropriate for assessing nerve function in this scenario. 1. A normal CT does not rule out functional nerve deficits; NCS/EMG is the key next step. 2. Breast cancer patients are at risk for both neoplastic and treatment-related brachial plexopathies. 3. Electrophysiological studies help differentiate demyelinating from axonal injuries. Recent guidelines and studies consistently support the early use of electrodiagnostic techniques (NCS/EMG) to differentiate types of plexopathy, helping to guide subsequent management decisions in patients with a history of cancer.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Back pain, L5 radiculopathy, muscle involved",
    "option_a": "(Gluteus medius) is the correct answer because the gluteus medius is predominantly innervated by the superior gluteal nerve\u2014with major contributions from the L5 nerve root. Other potential options might include muscles like the tibialis anterior, quadriceps, gastrocnemius, or gluteus maximus; however, these do not consistently correlate with isolated L5 involvement as clearly as the gluteus medius does.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "L5 radiculopathy is characterized by pain and neurological deficits along the distribution of the L5 nerve root. The gluteus medius muscle, primarily responsible for hip abducting strength and stabilization during gait, is largely innervated by the superior gluteal nerve, which carries fibers mainly from L5 (in addition to L4 and S1). Weakness in this muscle can thus be a sensitive indicator of L5 involvement. L5 radiculopathy typically results from mechanical compression or irritation of the L5 nerve root, most commonly due to a herniated disc or degenerative changes. Compression of the nerve root leads to impaired neural transmission, resulting in motor weakness (e.g., in the gluteus medius), sensory disturbances, and sometimes reflex changes. In patients presenting with lower back pain radiating to the lateral aspect of the leg, clinicians should evaluate for signs of L5 involvement, such as a positive Trendelenburg sign, which indicates gluteus medius weakness. This clinical finding supports the diagnosis of L5 radiculopathy, and imaging studies like MRI are often employed to confirm nerve root compression. Diagnosis involves detailed clinical history, neurological examination (focusing on motor strength, sensory testing, and reflexes), and confirmatory imaging such as MRI. Differential diagnoses include other radiculopathies (e.g., L4 or S1), peripheral neuropathies, and muscular pathologies. Electrophysiological studies can also assist in localizing the affected nerve root. Management of L5 radiculopathy includes a multimodal approach. Initially, conservative treatment with physical therapy aimed at strengthening the hip abductors, activity modification, and pain control using NSAIDs or neuropathic pain agents (e.g., gabapentin) is recommended. In cases with significant or progressive deficits, epidural steroid injections or surgical interventions may be considered. In the setting of pregnancy, non-pharmacologic treatments are preferred, and if medications are required, those with established safety profiles (such as certain NSAIDs, used with caution) should be selected. Lactating women should be managed similarly with a focus on agents with minimal excretion into breast milk, following current guidelines. Option A (Gluteus medius) is the correct answer because the gluteus medius is predominantly innervated by the superior gluteal nerve\u2014with major contributions from the L5 nerve root. Other potential options might include muscles like the tibialis anterior, quadriceps, gastrocnemius, or gluteus maximus; however, these do not consistently correlate with isolated L5 involvement as clearly as the gluteus medius does. 1. A positive Trendelenburg sign (hip drop on the contralateral side during single leg stance) should prompt evaluation of the gluteus medius function in suspected L5 radiculopathy. 2. Correlating clinical findings with imaging is essential in confirming the diagnosis. 3. Conservative management is typically first-line, with careful consideration of pregnancy and lactation when selecting pharmacologic agents. Recent clinical guidelines emphasize conservative management of radiculopathy, reserving invasive procedures for cases of severe neurological deficits or persistent pain. Physical therapy and exercise interventions have robust evidence supporting their use in radiculopathy. Additionally, current recommendations stress safe pharmacologic choices during pregnancy and lactation, advocating for treatments with well-established safety profiles.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario typical for GBS except that he had bone pain with recent vaccination asking what to see on day 5 on NCS/EMG",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Guillain-Barr\u00e9 syndrome (GBS) is an acute immune-mediated disorder affecting the peripheral nerves, most commonly in its acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant. It is often triggered by infections or vaccinations. Early in its course, electrophysiological studies are used to detect demyelinating changes, which include prolonged distal motor latencies and slowed conduction. In AIDP, an autoimmune attack on Schwann cell membranes leads to segmental demyelination. This process results in slowed nerve conduction due to impaired saltatory transmission. Initially, the axons remain intact, leading to normal compound muscle action potential (CMAP) amplitudes, while conduction slowing can prolong latencies. Sensory fibers may also be affected, which can lead to diminished or absent sensory nerve action potentials (SNAPs). Clinically, patients with GBS present with progressive weakness and areflexia. Sensory symptoms might be less pronounced or even absent, but when present, they correlate with the electrophysiological finding of abnormal SNAPs. The bone pain noted in the scenario, although not a classic feature of GBS, can sometimes follow vaccination and should not distract from the overall clinical pattern seen in AIDP. The differential diagnosis includes other causes of acute weakness such as spinal cord compression, myasthenia gravis, and acute myopathies. In GBS, nerve conduction studies are pivotal. On day 5, typical findings include prolonged distal motor latencies with relatively preserved CMAP amplitudes (given that axonal integrity is maintained early) and abnormal or absent SNAPs reflecting sensory fiber involvement. This contrasts with a completely normal study or patterns suggestive of primary axonal injury. The cornerstone of GBS management is immunotherapy with intravenous immunoglobulin (IVIG) or plasmapheresis. Both treatment modalities are similarly effective and are considered safe during pregnancy and lactation; however, IVIG is often preferred because of its ease of administration and safety profile. Supportive care, including respiratory monitoring and managing autonomic dysfunction, is critical. In pregnant patients, careful monitoring and multidisciplinary coordination are required to balance maternal and fetal well-being. Option (a) indicating normal CMAP, SNAP, and latencies is incorrect because electrophysiological changes, particularly prolonged latencies due to demyelination, are expected as early manifestations. Option (c) is incomplete and misleading, as decreased recruitment and other later features typically develop with disease progression. Option (b) \u2013 showing prolonged latency, normal CMAP, and absent SNAPs \u2013 best captures the early changes seen in GBS on day 5. \u2022 Early nerve conduction studies in GBS may only show subtle abnormalities; serial testing can be useful. \n\u2022 Management with IVIG is safe during pregnancy and lactation. \n\u2022 Although bone pain is an atypical finding, the overall clinical and electrophysiological picture should guide the diagnosis. Recent guidelines and studies support the use of electrophysiological testing to detect early demyelination in GBS. The American Academy of Neurology and other expert groups endorse IVIG as an effective and safe treatment option for patients with GBS, including those who are pregnant or lactating.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with symmetrical proximal and distal weakness, toes and finger numbness, fasciculation, foot drop during the course of the disease what is the dx",
    "option_a": "(LEMS) is incorrect because LEMS is predominantly a presynaptic neuromuscular junction disorder with autonomic dysfunction and lacks significant sensory involvement. Option b (MMN) is incorrect because MMN typically causes an asymmetric, purely motor neuropathy without sensory deficits. Option c (CIDP) correctly matches the clinical picture of symmetrical weakness with sensory symptoms and secondary axonal loss leading to fasciculations and foot drop.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) is an immune-mediated neuropathy characterized by a chronic course of demyelination affecting both motor and sensory nerves. It typically presents with symmetrical proximal and distal weakness combined with sensory deficits. CIDP is caused by an aberrant immune response targeting the myelin sheath of peripheral nerves. The resulting demyelination leads to decreased nerve conduction velocities. Over time, secondary axonal degeneration may occur, which can explain the presence of fasciculations. Recent studies support the role of both cellular and humoral immunity in its pathogenesis. Clinically, patients with CIDP often present with gradually progressive limb weakness (both proximal and distal) and sensory disturbances like numbness and tingling. Foot drop can result from weakness of the distal muscles. Although fasciculations are more common in conditions with primary axonal degeneration (e.g., motor neuron disease), in CIDP they can be seen in cases with significant secondary axonal loss. The diagnosis of CIDP is based on clinical history, neurological examination, and electrophysiological studies demonstrating demyelination (e.g., slowed conduction velocities, conduction block, prolonged distal latencies). Cerebrospinal fluid analysis may show albuminocytological dissociation. Differential diagnoses include LEMS (which primarily affects neuromuscular transmission without sensory involvement) and multifocal motor neuropathy (MMN), which is purely motor in nature with an asymmetric distribution. First-line treatments for CIDP include intravenous immunoglobulin (IVIG), corticosteroids, and plasmapheresis. If a patient fails to respond, immunosuppressive agents may be considered. In pregnancy and lactation, IVIG is generally favored due to its established safety profile, while corticosteroid use should be carefully monitored to balance maternal benefits against potential fetal risks. Option a (LEMS) is incorrect because LEMS is predominantly a presynaptic neuromuscular junction disorder with autonomic dysfunction and lacks significant sensory involvement. Option b (MMN) is incorrect because MMN typically causes an asymmetric, purely motor neuropathy without sensory deficits. Option c (CIDP) correctly matches the clinical picture of symmetrical weakness with sensory symptoms and secondary axonal loss leading to fasciculations and foot drop. 1) Always consider CIDP in patients with chronic, symmetrical motor and sensory deficits. 2) Electrophysiologic studies are key in differentiating demyelinating neuropathies from other neuromuscular disorders. 3) Early treatment can prevent permanent axonal loss. Recent guidelines by the European Federation of Neurological Societies (EFNS) and the American Academy of Neurology emphasize the importance of electrophysiologic criteria in diagnosing CIDP and support IVIG and corticosteroids as first-line treatments. Ongoing research is focused on identifying biomarkers that may predict treatment response.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario suggestive of Mononeuritis multiplex with pathology showing monoclonular cells and necrotizing vasculitis",
    "option_a": "is correct as it directly addresses the combination of clinical and pathological findings (mononeuritis multiplex with monoclonal cell infiltrate and necrotizing vasculitis). Other distractor options like diabetic neuropathy, amyloid neuropathy, infectious neuropathy, or neoplastic infiltration do not present with such vasculitic pathology.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Vasculitic neuropathy is a manifestation of systemic or isolated vasculitis wherein inflammation of blood vessels leads to ischemic injury of peripheral nerves. It often presents as mononeuritis multiplex, where discrete nerves are affected in a multifocal, asymmetric distribution. The underlying mechanism involves necrotizing vasculitis that damages the vessel walls supplying nerves. This results in ischemia and infarction of nerve fibers. The presence of monoclonal cell infiltrates and necrosis on a nerve or muscle biopsy strongly supports a vasculitic process. The inflammation disrupts the blood-nerve barrier, contributing to the clinical deficits. Patients typically present with painful, asymmetric deficits affecting motor and sensory functions in different nerve territories. The biopsy findings of monoclonal cells and necrotizing vasculitis clinch the diagnosis. Other causes of mononeuritis multiplex such as diabetic neuropathy or amyloid neuropathy usually lack these specific inflammatory changes. The diagnostic work-up includes nerve conduction studies and, importantly, nerve biopsy which reveals the histopathological hallmark of vasculitic neuropathy. Differential diagnoses include diabetic neuropathy, amyloid neuropathy, infectious or paraneoplastic processes, and neoplastic infiltration; each lacks the combination of clinical mononeuritis multiplex with necrotizing vasculitis on pathology. The cornerstone of treatment is immunosuppressive therapy. High-dose corticosteroids are generally first-line, often combined with cytotoxic agents (such as cyclophosphamide) in cases of systemic vasculitis. In pregnancy, corticosteroids are relatively safe while the use of potent immunosuppressants should be cautiously balanced with maternal and fetal risks, typically employing the lowest effective doses and considering alternative therapies if possible. Option a is correct as it directly addresses the combination of clinical and pathological findings (mononeuritis multiplex with monoclonal cell infiltrate and necrotizing vasculitis). Other distractor options like diabetic neuropathy, amyloid neuropathy, infectious neuropathy, or neoplastic infiltration do not present with such vasculitic pathology. 1) Nerve biopsy is the definitive diagnostic tool in suspected vasculitic neuropathy. 2) Early detection and treatment can prevent irreversible nerve damage. 3) Always correlate clinical findings with histopathological evidence. Recent literature supports the early initiation of immunosuppressive therapy in vasculitic neuropathy to halt nerve damage. There is also emerging interest in biologic agents for refractory cases, though their use in pregnancy remains limited to case-by-case assessments.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario suggestive of amyloidosis, autonomic symptoms, LL pain, and carpel tunnel which will confirm the dx",
    "option_a": "(fat pad biopsy) is correct as it directly confirms tissue amyloid deposition, which is the definitive diagnostic step. Option b (immunofixation) and Option c (protein electrophoresis) are useful screening tests for monoclonal proteins but do not confirm the presence of amyloid deposits.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Amyloidosis is a disorder characterized by the extracellular deposition of misfolded protein fibrils in various tissues, including the peripheral nerves. When it involves the nerves, it may present with autonomic dysfunction, neuropathic pain, and conditions like carpal tunnel syndrome due to amyloid deposition in tendinous structures. Amyloid deposits, commonly composed of immunoglobulin light chains (in AL amyloidosis) or transthyretin (in ATTR amyloidosis), accumulate in tissues and disrupt normal organ function. In neuropathy, these deposits interfere with nerve conduction and structural integrity, leading to both sensory and autonomic dysfunction. Patients with systemic amyloidosis can present with a constellation of symptoms such as autonomic features (e.g., orthostatic hypotension), lower limb pain, and entrapment neuropathies like carpal tunnel syndrome. The confirmation of amyloid deposition through tissue biopsy is critical for diagnosis. Fat pad biopsy, particularly an abdominal fat pad aspirate stained with Congo red, is a minimally invasive gold-standard test for demonstrating amyloid deposits. Differential diagnoses include other causes of neuropathy such as diabetic neuropathy or chronic inflammatory demyelinating polyneuropathy, but these do not show amyloid deposition on tissue staining. The treatment strategy depends on the type of amyloidosis. In AL amyloidosis, management includes chemotherapy regimens to reduce light chain production and possibly autologous stem cell transplantation. For ATTR, newer agents that stabilize or silence transthyretin are available. In pregnancy and lactation, management requires careful consideration: chemotherapeutic agents are usually contraindicated, and treatment plans may need modification until postpartum, with supportive care playing a larger role in the interim. Option a (fat pad biopsy) is correct as it directly confirms tissue amyloid deposition, which is the definitive diagnostic step. Option b (immunofixation) and Option c (protein electrophoresis) are useful screening tests for monoclonal proteins but do not confirm the presence of amyloid deposits. 1) A fat pad biopsy is the preferred initial confirmatory test for suspected systemic amyloidosis due to its high sensitivity and minimal invasiveness. 2) Congo red staining with apple-green birefringence under polarized light is pathognomonic for amyloid deposits. 3) Always differentiate between screening tests and confirmatory tissue diagnosis. Recent advances emphasize the importance of early tissue confirmation of amyloidosis, as early intervention with novel targeted therapies can potentially alter the disease course. Guidelines now recommend using fat pad biopsy as part of the initial workup in suspected cases.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "CMT2a what to expect",
    "option_a": "(upper limb > lower limb involvement) is correct as it reflects the atypical clinical pattern of CMT2A seen in some patients. Option b (loss of snaps) is not a recognized clinical feature in CMT2A or peripheral neuropathies in general and is therefore incorrect.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Charcot-Marie-Tooth disease type 2A (CMT2A) is a hereditary neuropathy primarily affecting the axons of peripheral nerves. It is most commonly caused by mutations in the MFN2 gene, which is critical for mitochondrial fusion and function. Mutations in the MFN2 gene lead to dysfunctional mitochondrial dynamics, resulting in axonal degeneration and impaired nerve function. Although many forms of CMT typically exhibit a length-dependent pattern with more pronounced lower limb involvement, CMT2A can have an atypical distribution with earlier or more prominent impairment of the upper limbs. Patients with CMT2A present with progressive weakness and atrophy in the limbs along with sensory deficits. The atypical feature highlighted in this question\u2014upper limb involvement being greater than lower limb involvement\u2014helps differentiate CMT2A from other forms of CMT, which usually have distal lower limb predominance. Diagnosis is based on clinical findings, electrophysiological studies showing axonal neuropathy, and genetic testing confirming an MFN2 mutation. Differential diagnoses include other hereditary neuropathies (e.g., CMT1 which is demyelinating with slowed nerve conduction velocities) and acquired neuropathies, but the genetic and electrophysiological profile helps distinguish CMT2A. There is no cure for CMT2A; management is largely supportive. This includes physical and occupational therapy, the use of orthotic devices to aid ambulation, and surgical interventions when necessary. Genetic counseling is important for affected families. In pregnancy and lactation, management remains supportive, with emphasis on maintaining mobility and preventing falls while avoiding medications that could exacerbate neuropathic symptoms. Option a (upper limb > lower limb involvement) is correct as it reflects the atypical clinical pattern of CMT2A seen in some patients. Option b (loss of snaps) is not a recognized clinical feature in CMT2A or peripheral neuropathies in general and is therefore incorrect. 1) CMT2A should be suspected in patients with an atypical pattern of limb involvement, especially with early upper limb weakness. 2) Genetic testing for MFN2 mutations is crucial when CMT2A is suspected. 3) Supportive management and therapy can significantly improve quality of life, even though there is no cure. Recent research has further elucidated the role of mitochondrial dysfunction in CMT2A, and ongoing clinical trials are investigating potential gene-targeted therapies. However, current management remains focused on symptomatic relief and supportive care.",
    "exam_year": "2022",
    "exam_type": "Part II"
  }
]